Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01808248 · ClinicalTrials.gov registry record · Phase 2

Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

A Phase 2 study of Hepatitis C, sponsored by Gilead Sciences.

Completed
Registry status
Phase 2
Development phase
47
Enrollment target
1
Study location

NCT01808248 is a Phase 2 study of Hepatitis C that has completed, run by Gilead Sciences. The registered enrollment target is 47 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01808248, a Phase 2 study of Hepatitis C, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 2
Development phase
47 participants
Enrollment target
1
Study location

Study Summary

This study is to evaluate the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF) in combination with peginterferon alfa 2a (PEG) and ribavirin (RBV) administered for 12 weeks in participants with chronic genotype 2 or 3 hepatitis C virus (HCV) infection who have previously failed prior treatment with an interferon-based regimen.

Conditions Studied

Hepatitis C

Interventions

  • DRUG SOF
  • DRUG RBV
  • DRUG PEG

Study Locations (1)

Texas

  • Alamo Medical Research - San Antonio

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2013-02
Est. Completion 2013-12
Phase Phase 2

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01808248

The ClinicalTrials.gov registry entry for NCT01808248 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (98% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 3 interventions - of which SOF is the first listed.

NCT01808248 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01808248 about?

NCT01808248 is a clinical study titled "Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3". This study is to evaluate the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF) in combination with peginterferon alfa 2a (PEG) and ribavirin (RBV) administered for 12 weeks in participants with chronic genotype 2 or 3 hepatitis C virus (HCV) infection who have previously failed prior...

What is the current status of trial NCT01808248?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2013-02. Estimated completion is 2013-12.

What conditions does trial NCT01808248 study?

This clinical trial studies the following conditions: Hepatitis C.

What interventions are being tested in trial NCT01808248?

The interventions under investigation include: SOF (DRUG), RBV (DRUG), PEG (DRUG).

Who is sponsoring clinical trial NCT01808248?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01808248 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatitis C

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.